Abstract
Tocilizumab, a monoclonal antibody targeting the IL-6 receptor, has recently been added to the therapeutic armamentarium against rheumatoid arthritis (RA). Despite its overall safety, concerns have been raised regarding diverticular perforation in patients receiving the drug. The aim of our research was to document the incidence of diverticular disease in RA patients treated in the pre-disease-modifying anti-rheumatic drug (DMARD) era, following treatment with conventional DMARDs, and subsequent to tocilizumab therapy. We performed a systematic literature review in MEDLINE, EMBASE, Conference Proceedings Citation Index–Science, Cochrane Central Register of Controlled Trials and Current Controlled Trials up to Nov. 2010. The publication titles and abstracts were independently assessed by two reviewers for relevance and quality, and the review was conducted following guidelines from the Centre for Reviews and Dissemination. In the pre-DMARD period of RA management, where patients were largely treated with NSAIDs and corticosteroids, gastrointestinal (GI) complications were a substantial cause of mortality with diverticulitis and colonic ulcers accounting for almost a third of GI-related deaths. In contrast, our search did not reveal any evidence of diverticular perforation in patients treated with conventional DMARDs. Eighteen cases of lower GI perforation (16 of whom had diverticulitis) have been documented in recent conference proceedings following tocilizumab treatment in clinical trials, with a lower GI perforation rate of 1.9 per 1,000 patient years (PY). This lies between the reported rate of GI perforations for corticosteroids and anti-TNF-α agents in the United Health Care database, with rates of 3.9 per 1,000 PY (95% CI 3.1–4.8) and 1.3 per 1,000 PY (95% CI 0.8–1.9), respectively. The majority of these patients were concurrently prescribed NSAIDs and/or long-term corticosteroids. Traditional DMARD therapy for RA appears not only to have modified the risk of lower GI perforation but prevented it. The risk of diverticular perforation may be slightly higher in patients treated with tocilizumab compared with conventional DMARDs or anti-TNF agents, but lower than that for corticosteroids. The mechanism of action of IL-6 antagonism in the pathophysiology of diverticular perforation has yet to be elucidated.
Similar content being viewed by others
References
Wolfe F, Rasker JJ, Boers M et al (2007) Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum 57:935–942
Haraoui B (2005) The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol 72:46–47
Hyrich KL, Silman AJ, Watson KD et al (2004) Anti-tumour necrosis factor a therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 63:1538–1543
Emery P, Keystone E, Tony HP et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–1523
Centre for Reviews and Dissemination (2011) Systematic reviews. Centre for Reviews and Dissemination guidance for undertaking reviews in health care. http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf. Accessed 5 Aug 2011
Prior P, Symmons DPM, Scott DL et al (1984) Cause of death in rheumatoid arthritis. Rheumatology 23:92–99
Allbeck P, Ahlbom A, Allander E (1981) Increased mortality among persons with rheumatoid arthritis but where RA does not appear on the death certificate. Scand J Rheumatol 10:301–306
Curtis JR, Xie F, Chen L et al (2011) The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum 63:346–351
Mpofu S, Mpofu CM, Hutchinson D et al (2004) Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis 63:588–590
Foutch PG (1995) Diverticular bleeding: are nonsteroidal anti-inflammatory drugs risk factors for hemorrhage and can colonoscopy predict outcome for patients? Am J Gastroenterol 90:1779–1784
Peura DA, Lanza FL, Gostout CJ et al (1997) The American College of Gastroenterology Bleeding Registry: preliminary findings. Am J Gastroenterol 92:924–928
Goh H, Bourne R (2002) Non-steroidal anti-inflammatory drugs and perforated diverticular disease: a case-control study. Ann R Coll Surg Engl 84:93–96
Laine L, Smith R, Min K et al (2006) Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 24:751–767
Eaves R, Hansky J, Wallis P (1982) Gold induced enterocolitis: case report and a review of the literature. Aust N Z J Med 12:617–620
Corsi F, Previde P, Colombo F et al (2006) Two cases of intestinal perforation in patients on anti-rheumatic treatment with etanercept. Clin Exp Rheumatol 24:113
Piekarek K, Israelsson LA (2008) Perforated colonic diverticular disease: the importance of NSAIDs, opioids, corticosteroids, and calcium channel blockers. Int J Colorectal Dis 23:1193–1197
Van Vollenhoven RF, Keystone EC, Furie R et al (2009) Gastrointestinal safety in patients with rheumatoid arthritis treated with tocilizumab: data from Roche clinical trials [abstract]. Arthritis Rheum 60 Suppl:S602
Hughes LE (1969) Postmortem survey of diverticular disease of the colon. I. Diverticulosis and diverticulitis. Gut 10:336–344
Morris CR, Harvey IM, Stebbings WS et al (2003) Anti-inflammatory drugs, analgesics and the risk of perforated colonic diverticular disease. Br J Surg 90:1267–1272
Hart AR, Kennedy HJ, Stebbings WS et al (2000) How frequently do large bowel diverticula perforate? An incidence and cross-sectional study. Eur J Gastroenterol Hepatol 12:661–665
Hernandez-Diaz S, Rodriguez LA (2002) Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 55:157–163
Morris CR, Harvey IM, Stebbings WS et al (2008) Incidence of perforated diverticulitis and risk factors for death in a UK population. Br J Surg 95:876–881
Chan FKL, Cryer B, Goldstein JL et al (2010) A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol 37:167–174
Lanas A (2010) A review of gastrointestinal safety data—a gastroenterologist’s perspective. Rheumatology 49:3–10
Allbeck P (1982) Increased mortality in rheumatoid arthritis. Scand J Rheumatol 11:81–86
Takeuchi K, Kuroda Y (2000) Rheumatoid vasculitis with multiple intestinal ulcerations: report of a case. Ryumachi 40:639–643
Petersen P, Christiansen P, Jensen P (1983) Mesenterial rheumatoid arteritis. A case of ischemic necrosis of small intestine. Ugeskr Laeger 145:1689–1690
Hay JM, Testart J (1974) Periarteritis nodosa and colonic perforation. J Chir 107:313–315
Kawashima I, Matsuoka Y, Fukuda J et al (1996) A case of perforated appendix caused by secondary amyloidosis associated with rheumatoid arthritis. Jpn J Gastroenterol 93:569–572
Leifeld L, Kruis W (2008) Modern therapy of diverticular disease. Internist 49:1415–1416
Pham T, Claudepierre P, Constantin A et al (2010) Tocilizumab: therapy and safety management. Joint Bone Spine 77:S3–S100
Khader A, Guglani L (2010) Th17 cytokines in mucosal immunity and inflammation. Curr Opin HIV AIDS 5:120–127
Horiuchi T, Mitoma H, Harashima S et al (2010) Transmembrane TNF-α: structure, function and interaction with anti-TNF agents. Rheumatology 49:1215–1228
Kopf M, Bachmann M, Marsland B (2010) Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 9:703–718
Conflict of interest
Andrew Östör has received support from (including attendance at conferences), undertakes clinical trials for and acts as a consultant to Roche, Chugai, Schering–Plough/MSD, Abbott, Wyeth, BMS, GSK, MerckSorono and UCB. Other authors have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gout, T., Östör, A.J.K. & Nisar, M.K. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 30, 1471–1474 (2011). https://doi.org/10.1007/s10067-011-1827-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-011-1827-x